



Company Overview

Aethlon Medical develops immunotherapeutic technologies to combat infectious disease and cancer. To augment the body's natural immune defenses, the Aethlon Hemopurifier® reduces the presence of circulating viruses in infected individuals. The technology provides a first-line candidate defense against viruses that are not addressed with proven drug therapies, including natural occurring pandemic threats and agents of bioterrorism. The Hemopurifier® can also be deployed as a strategy to improve the benefit of approved antiviral drug regimens. At present, the Hemopurifier® is being advanced in the United States under an FDA approved clinical study. Aethlon Medical is also investigating the potential use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients. Aethlon Medical is also the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE). ESI's TauSome™ biomarker is being clinically evaluated as the basis for a blood-based test to identify CTE in living individuals.

Aethlon Medical Announces Fiscal 2018 Results

Jun 8 2018, 4:15 PM EDT

Aethlon Medical To Release 2018 Fiscal Year End Financial Results and Host Conference Call on June 8, 2018

May 31 2018, 8:45 AM EDT

Study of Blood Test to Detect and Monitor Chronic Traumatic Encephalopathy (CTE) in Former NFL Players Set for Kick-Off in Phoenix

Mar 22 2018, 8:00 AM EDT

Stock Overview

Symbol	AEMD
Exchange	Nasdaq
Shares OS	17,761,206
Market Cap	\$23.09M
Last Price	\$1.2999
52-Week	\$0.7906 - \$3.85

06/22/2018 04:00 PM EDT

Investor Relations

CORE IR
John Marco
T: 516-222-2560
johnm@coreir.com

Management Team

James A. Joyce

Chief Executive Officer and Director

Rodney S. Kenley

President

James B. Frakes

Chief Financial Officer and Senior Vice President – Finance

Michael Jacobs

Senior Scientist

Annette Marleau, PhD

Director of Research

Aethlon Medical, Inc.

9635 Granite Ridge Drive
Suite 100
San Diego, CA 92123

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

